Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC H3B-6545 | 2052130-80-8 | 99.4% | 567.58 | 50 MG
Supplier: Medchemexpress LLC HY11259650MG
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. It is for research use only and not sold to patients.
- Oral, selective estrogen receptor covalent antagonist (SERCA).
- Designed for research into metastatic ER-positive, HER2-negative breast cancer.
- Potently antagonizes wild-type and mutant ERα in biochemical and cell-based assays.
- Inactivates wild-type and mutant ERα by targeting C530.
- Inhibits ERαWT activity and suppresses proliferation of ERαWT-positive breast cancer cell lines.
- Demonstrates superior efficacy to fulvestrant and tamoxifen in xenograft and patient-derived xenograft models.
- Well tolerated across a broad dose range in rats and monkeys.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?